248 related articles for article (PubMed ID: 9580622)
1. Short-term hemodynamic effects of mibefradil in dogs with chronic heart failure: comparison with diltiazem.
Shimoyama H; Sabbah HN; Tanimura M; Borzak S; Goldstein S
J Pharmacol Exp Ther; 1998 May; 285(2):746-52. PubMed ID: 9580622
[TBL] [Abstract][Full Text] [Related]
2. The effects of mibefradil, a novel calcium channel antagonist on ventricular arrhythmias induced by myocardial ischemia and programmed electrical stimulation.
Billman GE; Hamlin RL
J Pharmacol Exp Ther; 1996 Jun; 277(3):1517-26. PubMed ID: 8667218
[TBL] [Abstract][Full Text] [Related]
3. Hemodynamic profile of Ro 40-5967 in conscious rats: comparison with diltiazem, verapamil, and amlodipine.
Véniant M; Clozel JP; Hess P; Wolfgang R
J Cardiovasc Pharmacol; 1991; 18 Suppl 10():S55-8. PubMed ID: 1725005
[TBL] [Abstract][Full Text] [Related]
4. Potent vasodilatory with minor cardiodepressant actions of mibefradil in human cardiac tissue.
Brixius K; Mohr V; Müller-Ehmsen J; Hoischen S; Münch G; Schwinger RH
Br J Pharmacol; 1998 Sep; 125(1):41-8. PubMed ID: 9776342
[TBL] [Abstract][Full Text] [Related]
5. Effects of the calcium channel blockers, diltiazem and Ro 40-5967, on systemic haemodynamics and plasma noradrenaline levels in conscious dogs with pacing-induced heart failure.
Su J; Renaud N; Carayon A; Crozatier B; Hittinger L
Br J Pharmacol; 1994 Oct; 113(2):395-402. PubMed ID: 7834190
[TBL] [Abstract][Full Text] [Related]
6. Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade.
Noll G; Lüscher TF
Cardiology; 1998; 89 Suppl 1():10-5. PubMed ID: 9570424
[TBL] [Abstract][Full Text] [Related]
7. Divergent natriuretic action of calcium channel antagonists in mongrel dogs: renal haemodynamics as a determinant of natriuresis.
Honda M; Hayashi K; Matsuda H; Kubota E; Tokuyama H; Okubo K; Ozawa Y; Saruta T
Clin Sci (Lond); 2001 Oct; 101(4):421-7. PubMed ID: 11566080
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular T-type calcium channels: physiological and pharmacological significance.
Triggle DJ
J Hypertens Suppl; 1997 Dec; 15(5):S9-15. PubMed ID: 9481611
[TBL] [Abstract][Full Text] [Related]
9. Mibefradil, a pharmacologically distinct calcium antagonist.
Ernst ME; Kelly MW
Pharmacotherapy; 1998; 18(3):463-85. PubMed ID: 9620098
[TBL] [Abstract][Full Text] [Related]
10. Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist.
Petrie JR; Glen SK; MacMahon M; Crome R; Meredith PA; Elliott HL; Reid JL
J Hypertens; 1995 Dec; 13(12 Pt 2):1842-6. PubMed ID: 8903664
[TBL] [Abstract][Full Text] [Related]
11. Invasive pharmacodynamic characterization of combined ibopamine and calcium blocker therapy for heart failure.
Munger MA; Nara AR; Pospisil RA; Stoddard GJ; Schleman M
Pharmacotherapy; 1993; 13(3):218-23. PubMed ID: 8100627
[TBL] [Abstract][Full Text] [Related]
12. Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure.
Mulder P; Richard V; Compagnon P; Henry JP; Lallemand F; Clozel JP; Koen R; Macé B; Thuillez C
J Am Coll Cardiol; 1997 Feb; 29(2):416-21. PubMed ID: 9014998
[TBL] [Abstract][Full Text] [Related]
13. Hemodynamic effects of a calcium channel promoter, BAY y 5959, are preserved after chronic administration in ischemic heart failure in conscious dogs.
Yi GH; Burkhoff D; Zhang H; Zhu SM; Zwas D; Wang J
J Pharmacol Exp Ther; 1998 Aug; 286(2):760-6. PubMed ID: 9694931
[TBL] [Abstract][Full Text] [Related]
14. Effect of the novel T-selective calcium channel antagonist mibefradil on kidney function in comparison with amlodipine.
Greven J
Arzneimittelforschung; 1998 Aug; 48(8):806-10. PubMed ID: 9748707
[TBL] [Abstract][Full Text] [Related]
15. T- and L-type Ca2+-channel antagonists reduce contractility in guinea pig cardiac myocytes.
Hoischen S; Brixius K; Schwinger RH
J Cardiovasc Pharmacol; 1998 Aug; 32(2):323-30. PubMed ID: 9700997
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of mibefradil, verapamil, and amlodipine on myocardial function and intracellular Ca(2+) handling in rats with chronic myocardial infarction.
Min JY; Sandmann S; Meissner A; Unger T; Simon R
J Pharmacol Exp Ther; 1999 Dec; 291(3):1038-44. PubMed ID: 10565822
[TBL] [Abstract][Full Text] [Related]
17. Long-term antianginal and antiischemic effects of mibefradil, the novel T-type calcium channel blocker: a multicenter, double-blind, placebo-controlled, randomized comparison with sustained-release diltiazem.
Davies GJ; Kobrin I; Caspi A; Reisin LH; de Albuquerque DC; Armagnijan D; Coelho OR; Schneeweiss A
Am Heart J; 1997 Aug; 134(2 Pt 1):220-8. PubMed ID: 9313601
[TBL] [Abstract][Full Text] [Related]
18. Human vascular to cardiac tissue selectivity of L- and T-type calcium channel antagonists.
Sarsero D; Fujiwara T; Molenaar P; Angus JA
Br J Pharmacol; 1998 Sep; 125(1):109-19. PubMed ID: 9776350
[TBL] [Abstract][Full Text] [Related]
19. T-type and L-type calcium channel blockers exert opposite effects on renin secretion and renin gene expression in conscious rats.
Wagner C; Krämer BK; Hinder M; Kieninger M; Kurtz A
Br J Pharmacol; 1998 Jun; 124(3):579-85. PubMed ID: 9647484
[TBL] [Abstract][Full Text] [Related]
20. Myocardial perfusion distal to an acute or chronic coronary artery occlusion: effects of diltiazem and nifedipine.
Zyvoloski MG; Brooks HL; Gross GJ; Warltier DC
J Pharmacol Exp Ther; 1982 Aug; 222(2):494-500. PubMed ID: 7097568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
